Published in Nat Rev Rheumatol on October 01, 2009
Linear ubiquitination prevents inflammation and regulates immune signalling. Nature (2011) 4.85
The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov (2010) 2.23
Alarmins: awaiting a clinical response. J Clin Invest (2012) 2.19
Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy. J Exp Med (2013) 2.18
TNF-induced osteoclastogenesis and inflammatory bone resorption are inhibited by transcription factor RBP-J. J Exp Med (2012) 1.99
Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol (2009) 1.95
Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res (2010) 1.89
A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat Genet (2011) 1.78
Role of innate cytokines in mycobacterial infection. Mucosal Immunol (2011) 1.68
Autophagy: controlling cell fate in rheumatic diseases. Nat Rev Rheumatol (2016) 1.42
Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeleton. J Cell Biochem (2010) 1.16
CD23/FcεRII: molecular multi-tasking. Clin Exp Immunol (2010) 1.10
Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone. Mol Ther (2012) 1.10
Resurrection of a clinical antibody: template proteogenomic de novo proteomic sequencing and reverse engineering of an anti-lymphotoxin-α antibody. Proteomics (2011) 1.08
A brief comparison of the pathophysiology of inflammatory versus neuropathic pain. Curr Opin Anaesthesiol (2011) 1.08
Ubiquitin in the immune system. EMBO Rep (2013) 1.06
Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis. Rheumatology (Oxford) (2012) 1.04
Death receptor-ligand systems in cancer, cell death, and inflammation. Cold Spring Harb Perspect Biol (2013) 1.03
Treatment of experimental adjuvant arthritis with a novel folate receptor-targeted folic acid-aminopterin conjugate. Arthritis Res Ther (2011) 1.03
T cell stimulator cells, an efficient and versatile cellular system to assess the role of costimulatory ligands in the activation of human T cells. J Immunol Methods (2010) 1.02
Mesenchymal stem cells as a potent cell source for articular cartilage regeneration. World J Stem Cells (2014) 1.01
Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus. Front Immunol (2015) 0.97
Akt fine-tunes NF-κB-dependent gene expression during T cell activation. J Biol Chem (2011) 0.97
Successful aging as a continuum of functional independence: lessons from physical disability models of aging. Aging Dis (2011) 0.94
Inflammation: cytokines and RNA-based regulation. Wiley Interdiscip Rev RNA (2010) 0.92
The yin and yang of regulatory T cells and inflammation in RA. Nat Rev Rheumatol (2010) 0.92
Interferon gamma-dependent intestinal pathology contributes to the lethality in bacterial superantigen-induced toxic shock syndrome. PLoS One (2011) 0.92
Inhibitor of apoptosis proteins (IAPs) and their antagonists regulate spontaneous and tumor necrosis factor (TNF)-induced proinflammatory cytokine and chemokine production. J Biol Chem (2012) 0.92
Alzheimer's disease risk alleles in TREM2 illuminate innate immunity in Alzheimer's disease. Alzheimers Res Ther (2013) 0.91
Prevention of arthritis by locally synthesized recombinant antibody neutralizing complement component C5. PLoS One (2013) 0.90
Systemically administered anti-TNF therapy ameliorates functional outcomes after focal cerebral ischemia. J Neuroinflammation (2014) 0.90
Investigation of the role of endosomal Toll-like receptors in murine collagen-induced arthritis reveals a potential role for TLR7 in disease maintenance. Arthritis Res Ther (2012) 0.90
Negative regulation of NF-κB and its involvement in rheumatoid arthritis. Arthritis Res Ther (2011) 0.89
Site-directed mutagenesis of the CC chemokine binding protein 35K-Fc reveals residues essential for activity and mutations that increase the potency of CC chemokine blockade. Mol Pharmacol (2011) 0.88
Mechanisms of human autoimmunity. J Clin Invest (2015) 0.87
Feedback inhibition of osteoclastogenesis during inflammation by IL-10, M-CSF receptor shedding, and induction of IRF8. Ann N Y Acad Sci (2011) 0.86
Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Arthritis Res Ther (2012) 0.86
Long-term effects of anti-tumour necrosis factor therapy on weight in patients with rheumatoid arthritis. Clin Rheumatol (2011) 0.86
Predictors of European League Against Rheumatism (EULAR) good response, DAS-28 remission and sustained responses to TNF-inhibitors in rheumatoid arthritis: a prospective study in refractory disease. Springerplus (2015) 0.85
A role for syntaxin 3 in the secretion of IL-6 from dendritic cells following activation of toll-like receptors. Front Immunol (2015) 0.84
Central but not systemic administration of XPro1595 is therapeutic following moderate spinal cord injury in mice. J Neuroinflammation (2014) 0.84
Breaking Free of Control: How Conventional T Cells Overcome Regulatory T Cell Suppression. Front Immunol (2016) 0.83
Maternal death following cardiopulmonary collapse after delivery: amniotic fluid embolism or septic shock due to intrauterine infection? Am J Reprod Immunol (2010) 0.83
A TNF variant that associates with susceptibility to musculoskeletal disease modulates thyroid hormone receptor binding to control promoter activation. PLoS One (2013) 0.82
The role of neutrophils and NETosis in autoimmune and renal diseases. Nat Rev Nephrol (2016) 0.82
Profiling drugs for rheumatoid arthritis that inhibit synovial fibroblast activation. Nat Chem Biol (2016) 0.82
Enriched protein screening of human bone marrow mesenchymal stromal cell secretions reveals MFAP5 and PENK as novel IL-10 modulators. Mol Ther (2014) 0.82
Protein engineering and preclinical development of a GM-CSF receptor antibody for the treatment of rheumatoid arthritis. Br J Pharmacol (2013) 0.81
Pharmacological inhibition of TPL2/MAP3K8 blocks human cytotoxic T lymphocyte effector functions. PLoS One (2014) 0.81
Enhanced stability of tristetraprolin mRNA protects mice against immune-mediated inflammatory pathologies. Proc Natl Acad Sci U S A (2016) 0.81
Anti-inflammatory and anti-arthritic activities of 3,4-dihydro-2,2-dimethyl-2H-naphthol[1,2-b]pyran-5,6-dione (β-lapachone). Inflamm Res (2012) 0.80
Emerging MRI methods in rheumatoid arthritis. Nat Rev Rheumatol (2010) 0.80
Trojan horses and guided missiles: targeted therapies in the war on arthritis. Nat Rev Rheumatol (2015) 0.80
Double-antiangiogenic protein DAAP targeting vascular endothelial growth factor A and angiopoietins attenuates collagen-induced arthritis. Arthritis Res Ther (2013) 0.80
NF-κB as a Therapeutic Target in Inflammatory-Associated Bone Diseases. Adv Protein Chem Struct Biol (2016) 0.78
Tregalizumab - A Monoclonal Antibody to Target Regulatory T Cells. Front Immunol (2016) 0.78
Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis. Dig Dis Sci (2010) 0.78
Infliximab therapy impacts the peripheral immune system of immunomodulator and corticosteroid naïve patients with Crohn's disease. Gut Liver (2011) 0.77
Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt. Biomed Res Int (2015) 0.77
TRAF1/C5 but not PTPRC variants are potential predictors of rheumatoid arthritis response to anti-tumor necrosis factor therapy. Biomed Res Int (2015) 0.77
Replacements of rare herbs and simplifications of traditional chinese medicine formulae based on attribute similarities and pathway enrichment analysis. Evid Based Complement Alternat Med (2013) 0.77
Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology (Oxford) (2015) 0.76
Delivery strategies to control inflammatory response: Modulating M1-M2 polarization in tissue engineering applications. J Control Release (2016) 0.76
A potential osteoporosis target in the FAS ligand/FAS pathway of osteoblast to osteoclast signaling. Ann Transl Med (2015) 0.75
A Fatal Case of Relapsing Pneumonia Caused by Legionella pneumophila in a Patient with Rheumatoid Arthritis After Two Injections of Adalimumab. Clin Med Insights Case Rep (2013) 0.75
Pneumococcal polyarticular septic arthritis after a single infusion of infliximab in a rheumatoid arthritis patient: a case report. J Med Case Rep (2012) 0.75
Tumor necrosis factor-alpha converting enzyme: Implications for ocular inflammatory diseases. Int J Biochem Cell Biol (2010) 0.75
Correlation of Demographic and Clinical Characteristics with Rheumatoid Factor Seropositivity in Rheumatoid Arthritis Patients. Malays J Med Sci (2016) 0.75
Anti-interleukin-6 therapy through application of a monogenic protein inhibitor via gene delivery. Sci Rep (2015) 0.75
TNF Blockade Maintains an IL-10(+) Phenotype in Human Effector CD4(+) and CD8(+) T Cells. Front Immunol (2017) 0.75
Hydrodynamic Gene Delivery of CC Chemokine Binding Fc Fusion Proteins to Target Acute Vascular Inflammation In Vivo. Sci Rep (2015) 0.75
Safety and clinical efficacy of golimumab in the treatment of arthritides. Drug Healthc Patient Saf (2010) 0.75
Rational design of antirheumatic prodrugs specific for sites of inflammation. Arthritis Rheumatol (2015) 0.75
Antibodies against ClC7 inhibit extracellular acidification-induced Cl⁻ currents and bone resorption activity in mouse osteoclasts. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.75
Treatment with anti-NAP monoclonal antibody reduces disease severity in murine model of novel angiogenic protein-induced or ovalbumin-induced arthritis. Clin Exp Immunol (2013) 0.75
Cell biology: Death by deacetylation. Nature (2012) 0.75
Is Immune Aging a Cause of Disease among the Elderly, or is it a Passive Indicator of General Decline of Physiologic Function? Aging Dis (2011) 0.75
Targeted Delivery of Neutralizing Anti-C5 Antibody to Renal Endothelium Prevents Complement-Dependent Tissue Damage. Front Immunol (2017) 0.75
Nanofluidic device for continuous multiparameter quality assurance of biologics. Nat Nanotechnol (2017) 0.75
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med (2001) 18.25
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med (1999) 11.62
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum (2006) 8.78
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum (2003) 8.50
Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J (1991) 8.31
Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med (1985) 8.16
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet (2008) 7.37
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis (2008) 6.97
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med (2005) 6.37
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum (2004) 6.22
Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature (1986) 5.68
Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol (2001) 5.59
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum (2006) 5.20
Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A (1992) 5.07
Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther (2007) 5.02
Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet (1989) 4.42
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum (1998) 4.37
Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum (2007) 3.99
Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med (2003) 3.89
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2002) 3.78
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis (2008) 3.45
Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis (2008) 3.42
Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum (2006) 3.29
TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) (2005) 2.69
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis (2008) 2.45
Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum (2005) 2.37
Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum (2004) 2.35
Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol (1991) 1.87
Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford) (2007) 1.77
Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. Cytokine (1990) 1.72
Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. J Immunol (1996) 1.69
The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol (2008) 1.64
Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis (2006) 1.56
Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum (2008) 1.52
Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med (2008) 1.51
Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw (1996) 1.47
Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1. Eur J Immunol (1999) 1.29
TNF-alpha drives human CD14+ monocytes to differentiate into CD70+ dendritic cells evoking Th1 and Th17 responses. J Immunol (2007) 1.21
Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? Ann Rheum Dis (2007) 1.18
Tumor necrosis factor (TNF) receptor expression in T lymphocytes. Differential regulation of the type I TNF receptor during activation of resting and effector T cells. J Immunol (1991) 1.17
Involvement of the 55- and 75-kDa tumor necrosis factor receptors in the generation of lymphokine-activated killer cell activity and proliferation of natural killer cells. J Immunol (1991) 1.16
Fibroblast biology. Signals targeting the synovial fibroblast in arthritis. Arthritis Res (2000) 1.09
Independent regulation of 55-kDa and 75-kDa tumor necrosis factor receptors during activation of human peripheral blood B lymphocytes. Eur J Immunol (1991) 1.04
Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry). Ann Rheum Dis (2010) 1.01
Antibody engineering to develop new antirheumatic therapies. Arthritis Res Ther (2009) 0.97
Unmasking of a protective tumor necrosis factor receptor I-mediated signal in the collagen-induced arthritis model. Arthritis Rheum (2009) 0.93
Abandoned therapies and unpublished trials in rheumatoid arthritis. Curr Opin Rheumatol (2003) 0.86
IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol (2011) 5.11
Role of interleukin-1beta in postoperative cognitive dysfunction. Ann Neurol (2010) 3.09
Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev (2010) 2.71
Tumor necrosis factor-alpha triggers a cytokine cascade yielding postoperative cognitive decline. Proc Natl Acad Sci U S A (2010) 2.70
TNF-alpha promotes fracture repair by augmenting the recruitment and differentiation of muscle-derived stromal cells. Proc Natl Acad Sci U S A (2011) 2.33
Alarmins: awaiting a clinical response. J Clin Invest (2012) 2.19
Selective blockade of tumor necrosis factor receptor I inhibits proinflammatory cytokine and chemokine production in human rheumatoid arthritis synovial membrane cell cultures. Arthritis Rheum (2013) 2.03
Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci U S A (2004) 1.95
A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum (2004) 1.67
A new JCI conflict-of-interest policy. J Clin Invest (2007) 1.61
The impact of IL-1 modulation on the development of lipopolysaccharide-induced cognitive dysfunction. Crit Care (2010) 1.59
Key differences in TLR3/poly I:C signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems. Blood (2007) 1.57
Reduction of cPLA2alpha overexpression: an efficient anti-inflammatory therapy for collagen-induced arthritis. Eur J Immunol (2008) 1.54
Blockade of NKG2D ameliorates disease in mice with collagen-induced arthritis: a potential pathogenic role in chronic inflammatory arthritis. Arthritis Rheum (2011) 1.52
T-cell-mediated signalling in immune, inflammatory and angiogenic processes: the cascade of events leading to inflammatory diseases. Curr Drug Targets Inflamm Allergy (2004) 1.47
The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis. Am J Pathol (2007) 1.47
VEGF expression in human macrophages is NF-kappaB-dependent: studies using adenoviruses expressing the endogenous NF-kappaB inhibitor IkappaBalpha and a kinase-defective form of the IkappaB kinase 2. J Cell Sci (2003) 1.46
Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis. Arthritis Rheum (2002) 1.40
Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. Circulation (2009) 1.38
Treatment of murine osteoarthritis with TrkAd5 reveals a pivotal role for nerve growth factor in non-inflammatory joint pain. Pain (2010) 1.37
Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arthritis Res Ther (2007) 1.35
Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade. Arthritis Rheum (2007) 1.34
Unexpected protective role for Toll-like receptor 3 in the arterial wall. Proc Natl Acad Sci U S A (2011) 1.31
Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis (2011) 1.31
Collagen-induced arthritis in C57BL/6 mice is associated with a robust and sustained T-cell response to type II collagen. Arthritis Res Ther (2007) 1.29
Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? Immunol Rev (2004) 1.29
A novel mechanism for TNF-alpha regulation by p38 MAPK: involvement of NF-kappa B with implications for therapy in rheumatoid arthritis. J Immunol (2004) 1.26
Molecular profile of peripheral blood mononuclear cells from patients with rheumatoid arthritis. Mol Med (2007) 1.24
Historical review: Cytokines as therapeutics and targets of therapeutics. Trends Pharmacol Sci (2004) 1.24
NF-κB as a target for modulating inflammatory responses. Curr Pharm Des (2012) 1.21
How does infliximab work in rheumatoid arthritis? Arthritis Res (2002) 1.20
Cytokines and anti-cytokine biologicals in autoimmunity: present and future. Cytokine Growth Factor Rev (2002) 1.18
Inhibitors of TLR8 reduce TNF production from human rheumatoid synovial membrane cultures. J Immunol (2008) 1.17
Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases. Curr Opin Pharmacol (2007) 1.17
Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther (2010) 1.14
Regulation of pain sensitivity in experimental osteoarthritis by the endogenous peripheral opioid system. Arthritis Rheum (2008) 1.12
Vascular endothelial growth factor signalling in endothelial cell survival: a role for NFkappaB. Biochem Biophys Res Commun (2005) 1.12
Heterogeneous requirement of IkappaB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis: implications for therapy. Arthritis Rheum (2003) 1.08
IL-10 inhibits transcription elongation of the human TNF gene in primary macrophages. J Exp Med (2010) 1.07
TNFalpha-induced macrophage chemokine secretion is more dependent on NF-kappaB expression than lipopolysaccharides-induced macrophage chemokine secretion. Eur J Immunol (2002) 1.06
Ikappa B kinase 2 but not NF-kappa B-inducing kinase is essential for effective DC antigen presentation in the allogeneic mixed lymphocyte reaction. Blood (2002) 1.05
CD200-Fc, a novel antiarthritic biologic agent that targets proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis. Arthritis Rheum (2008) 1.04
Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic target. Proc Natl Acad Sci U S A (2013) 1.03
Rac mediates TNF-induced cytokine production via modulation of NF-kappaB. Mol Immunol (2008) 1.03
Selective tumor necrosis factor receptor I blockade is antiinflammatory and reveals immunoregulatory role of tumor necrosis factor receptor II in collagen-induced arthritis. Arthritis Rheumatol (2014) 1.02
The toll-like receptor-nuclear factor kappaB pathway in rheumatoid arthritis. Front Biosci (2005) 1.02
Inhibition of p38 mitogen-activated protein kinase is effective in the treatment of experimental crescentic glomerulonephritis and suppresses monocyte chemoattractant protein-1 but not IL-1beta or IL-6. J Am Soc Nephrol (2007) 1.01
Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis. Arthritis Res Ther (2008) 1.00
TREM-1 expression is increased in the synovium of rheumatoid arthritis patients and induces the expression of pro-inflammatory cytokines. Rheumatology (Oxford) (2009) 1.00
Effective targeting of the tumor microenvironment for cancer therapy. Anticancer Res (2012) 0.98
Down-regulation of Th1-mediated pathology in experimental arthritis by stimulation of the Th2 arm of the immune response. Arthritis Rheum (2003) 0.97
SIGIRR/TIR-8 is an inhibitor of Toll-like receptor signaling in primary human cells and regulates inflammation in models of rheumatoid arthritis. Arthritis Rheum (2010) 0.94
Investigating the role of the interleukin-23/-17A axis in rheumatoid arthritis. Rheumatology (Oxford) (2009) 0.93
Nonsteroidal anti-inflammatory drugs increase TNF production in rheumatoid synovial membrane cultures and whole blood. J Immunol (2010) 0.93
Advanced glycation end products upregulate angiogenic and pro-inflammatory cytokine production in human monocyte/macrophages. Cytokine (2004) 0.92
The angiogenesis inhibitor protease-activated kringles 1-5 reduces the severity of murine collagen-induced arthritis. Arthritis Res Ther (2002) 0.90
Resistance to regulatory T cell-mediated suppression in rheumatoid arthritis can be bypassed by ectopic foxp3 expression in pathogenic synovial T cells. Proc Natl Acad Sci U S A (2011) 0.90
Cytokine-stimulated T cells induce macrophage IL-10 production dependent on phosphatidylinositol 3-kinase and p70S6K: implications for rheumatoid arthritis. Arthritis Res (2001) 0.89
T cell-mediated signaling to vascular endothelium: induction of cytokines, chemokines, and tissue factor. J Leukoc Biol (2002) 0.88
Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis. Arthritis Res Ther (2003) 0.88
Tumour necrosis factor alpha as a therapeutic target for immune-mediated inflammatory diseases. Curr Opin Biotechnol (2004) 0.88
The pitfalls in the development of biologic therapy. Nat Clin Pract Rheumatol (2007) 0.88
Differential effects of Th1 versus Th2 cytokines in combination with hypoxia on HIFs and angiogenesis in RA. Arthritis Res Ther (2012) 0.88
The therapeutic activity of low-dose irradiation on experimental arthritis depends on the induction of endogenous regulatory T cell activity. Ann Rheum Dis (2010) 0.87
Resting CD4+ effector memory T cells are precursors of bystander-activated effectors: a surrogate model of rheumatoid arthritis synovial T-cell function. Arthritis Res Ther (2008) 0.87
Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis. J Pharmacol Exp Ther (2004) 0.87
Could toll-like receptors provide a missing link in chronic inflammation in rheumatoid arthritis? Lessons from a study on human rheumatoid tissue. Ann Rheum Dis (2007) 0.86
OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis. Proc Natl Acad Sci U S A (2014) 0.86
Emerging approaches for the therapy of autoimmune and chronic inflammatory disease. Curr Opin Immunol (2004) 0.86
Molecular therapeutic targets in rheumatoid arthritis. Expert Rev Mol Med (2005) 0.85
Regulation of the angiopoietin-Tie ligand-receptor system with a novel splice variant of Tie1 reduces the severity of murine arthritis. Rheumatology (Oxford) (2010) 0.83
Antagonism of the human epidermal growth factor receptor family controls disease severity in murine collagen-induced arthritis. Arthritis Rheum (2008) 0.83
IL-17 induces hyperalgesia via TNF-dependent neutrophil infiltration. Pain (2011) 0.83
RelB/p50 regulates TNF production in LPS-stimulated dendritic cells and macrophages. Cytokine (2013) 0.82
Gene expression profiling and functional analysis of angiogenic markers in murine collagen-induced arthritis. Arthritis Res Ther (2012) 0.82
Monoclonal antibodies in immune and inflammatory diseases. Curr Opin Biotechnol (2002) 0.81
RelB/p50 regulates CCL19 production, but fails to promote human DC maturation. Eur J Immunol (2009) 0.81
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum (2008) 0.80
Balance between activating NKG2D, DNAM-1, NKp44 and NKp46 and inhibitory CD94/NKG2A receptors determine natural killer degranulation towards rheumatoid arthritis synovial fibroblasts. Immunology (2014) 0.80
Directed issue: novel concepts in inflammation. Int J Biochem Cell Biol (2010) 0.79
Human epidermal growth factor receptor bispecific ligand trap RB200: abrogation of collagen-induced arthritis in combination with tumour necrosis factor blockade. Arthritis Res Ther (2011) 0.78
Targeting intracellular signaling: a novel approach to vaccination. Expert Rev Vaccines (2007) 0.78
New approaches to therapeutic immunomodulation for immune-mediated inflammatory disorders. Curr Opin Pharmacol (2004) 0.77
Reply: To PMID 23784528. Arthritis Rheumatol (2014) 0.75
High-efficiency gene transfer into nontransformed cells: utility for studying gene regulation and analysis of potential therapeutic targets. Arthritis Res (2002) 0.75
Anti-TNF Therapy. Microbiol Spectr (2016) 0.75
A conversation with Marc Feldmann. Interviewed by Ushma S. Neill. J Clin Invest (2014) 0.75
MRI-detected bone marrow edema in early rheumatoid arthritis. Nat Clin Pract Rheumatol (2008) 0.75
In memoriam: Professor Brian Maurice John Foxwell, 1956 to 2008. Arthritis Res Ther (2009) 0.75